NASDAQ:VERV Verve Therapeutics (VERV) Stock Forecast, Price & News $13.26 +0.30 (+2.31%) (As of 09/29/2023 ET) Add Compare Share Share Today's Range$12.79▼$13.4750-Day Range$11.42▼$20.7452-Week Range$11.25▼$40.88Volume985,181 shsAverage Volume718,416 shsMarket Capitalization$844.93 millionP/E RatioN/ADividend YieldN/APrice Target$30.83 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Verve Therapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside132.5% Upside$30.83 Price TargetShort InterestBearish27.86% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.45Based on 5 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($3.50) to ($3.62) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.67 out of 5 starsMedical Sector869th out of 972 stocksPharmaceutical Preparations Industry413th out of 454 stocks 3.3 Analyst's Opinion Consensus RatingVerve Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 5 buy ratings, 2 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $30.83, Verve Therapeutics has a forecasted upside of 132.5% from its current price of $13.26.Amount of Analyst CoverageVerve Therapeutics has only been the subject of 4 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted27.86% of the float of Verve Therapeutics has been sold short.Short Interest Ratio / Days to CoverVerve Therapeutics has a short interest ratio ("days to cover") of 19.4, which indicates bearish sentiment.Change versus previous monthShort interest in Verve Therapeutics has recently increased by 0.17%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldVerve Therapeutics does not currently pay a dividend.Dividend GrowthVerve Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for VERV. Previous Next 1.9 News and Social Media Coverage News SentimentVerve Therapeutics has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.69 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Verve Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 2 people have searched for VERV on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Verve Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Verve Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders21.40% of the stock of Verve Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions97.11% of the stock of Verve Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Verve Therapeutics are expected to decrease in the coming year, from ($3.50) to ($3.62) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Verve Therapeutics is -4.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Verve Therapeutics is -4.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVerve Therapeutics has a P/B Ratio of 1.48. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Verve Therapeutics (NASDAQ:VERV) StockVerve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.Read More VERV Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VERV Stock News HeadlinesSeptember 30, 2023 | americanbankingnews.comVerve Therapeutics, Inc. (NASDAQ:VERV) Given Consensus Recommendation of "Moderate Buy" by AnalystsSeptember 27, 2023 | finance.yahoo.comVerve Therapeutics (VERV) Soars 13.8%: Is Further Upside Left in the Stock?October 1, 2023 | Behind the Markets (Ad)[BREAKING] New "Living Missile" to Replace Nuclear MissilesCBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!September 26, 2023 | finance.yahoo.comVerve to Present Interim Data from the heart-1 Phase 1b Clinical Trial of VERVE-101 in HeFH Patients at the American Heart Association’s Scientific Sessions 2023September 25, 2023 | msn.comVerve's New Beat: CMO Onboard, Catalysts Ahead, But We're Dancing Solo For NowSeptember 21, 2023 | finance.yahoo.comVerve Therapeutics to Participate in the 2023 Cantor Global Healthcare ConferenceSeptember 18, 2023 | msn.comVerve names Frederick T. Fiedorek as Chief Medical OfficerSeptember 18, 2023 | markets.businessinsider.comVerve Therapeutics Names Frederick Fiedorek CMOOctober 1, 2023 | Behind the Markets (Ad)[BREAKING] New "Living Missile" to Replace Nuclear MissilesCBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!September 18, 2023 | finance.yahoo.comVerve Expands Leadership Team with Appointment of Frederick T. Fiedorek, M.D., as Chief Medical OfficerSeptember 14, 2023 | msn.comCantor Fitzgerald Reiterates Verve Therapeutics (VERV) Neutral RecommendationSeptember 11, 2023 | seekingalpha.comCracking The Cholesterol Code: Verve's High-Stakes BetAugust 31, 2023 | finance.yahoo.com1 Cathie Wood Stock That Could Go Parabolic SoonAugust 30, 2023 | markets.businessinsider.comCantor Fitzgerald Keeps Their Hold Rating on Verve Therapeutics (VERV)August 29, 2023 | markets.businessinsider.comExpert Ratings for Verve TherapeuticsAugust 18, 2023 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Replimune Group (REPL) and Verve Therapeutics (VERV)August 15, 2023 | msn.comGuggenheim Maintains Verve Therapeutics (VERV) Buy RecommendationAugust 14, 2023 | seekingalpha.comVerve Therapeutics, Inc. 2023 Q2 - Results - Earnings Call PresentationAugust 11, 2023 | msn.comCredit Suisse Reiterates Verve Therapeutics (VERV) Neutral RecommendationAugust 11, 2023 | finance.yahoo.comInvestors in Verve Therapeutics (NASDAQ:VERV) have unfortunately lost 47% over the last yearAugust 11, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Third Harmonic Bio, Inc. (THRD) and Verve Therapeutics (VERV)August 10, 2023 | msn.comVerve Therapeutics GAAP EPS of -$0.87 beats by $0.05, revenue of $2.09M beats by $1.42MAugust 10, 2023 | finance.yahoo.comVerve Therapeutics Highlights Recent Company Progress and Reports Second Quarter 2023 Financial ResultsAugust 10, 2023 | finance.yahoo.comVerve Therapeutics (VERV) Reports Q2 Loss, Tops Revenue EstimatesAugust 3, 2023 | finance.yahoo.comVerve Therapeutics to Present at the Canaccord 43rd Annual Growth ConferenceJuly 25, 2023 | finance.yahoo.comHow Much Upside is Left in Verve Therapeutics (VERV)? Wall Street Analysts Think 93.5%July 4, 2023 | bizjournals.comHow local researchers are turning Philadelphia into a hotspot for gene editingSee More Headlines Receive VERV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Verve Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address VERV Company Calendar Last Earnings8/10/2023Today10/01/2023Next Earnings (Estimated)11/06/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:VERV CUSIPN/A CIK1840574 Webvervetx.com Phone617-603-0070FaxN/AEmployees204Year FoundedN/APrice Target and Rating Average Stock Price Forecast$30.83 High Stock Price Forecast$55.00 Low Stock Price Forecast$13.00 Forecasted Upside/Downside+132.5%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($3.17) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-157,390,000.00 Net Margins-3,534.98% Pretax Margin-3,530.78% Return on Equity-37.08% Return on Assets-29.85% Debt Debt-to-Equity RatioN/A Current Ratio14.32 Quick Ratio14.32 Sales & Book Value Annual Sales$1.94 million Price / Sales435.53 Cash FlowN/A Price / Cash FlowN/A Book Value$8.94 per share Price / Book1.48Miscellaneous Outstanding Shares63,720,000Free Float50,085,000Market Cap$844.93 million OptionableNot Optionable Beta1.70 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Burt A. Adelman M.D. (Age 71)Co-Founder & Independent Chairman Comp: $87.55kDr. Sekar Kathiresan M.D. (Age 51)Co-Founder, CEO & Director Comp: $899.55kMr. Andrew D. Ashe J.D. (Age 56)Pres, COO & Gen. Counsel Comp: $703.85kDr. Andrew Bellinger M.D. (Age 45)Ph.D., Chief Scientific Officer & Chief Medical Officer Comp: $703.85kDr. Kiran Musunuru M.D.M.P.H., Ph.D., Co-Founder & Sr. Scientific AdvisorDr. J. Keith Joung M.D.Ph.D., Co-FounderDr. Anthony Philippakis M.D.Ph.D., Co-Founder & Scientific Advisory Board MemberDr. Barry S. Ticho FACC (Age 62)M.D., Ph.D., Co-Founder Mr. Issi Rozen M.B.A.Co-Founder & Strategic AdvisorMs. Allison Dorval (Age 47)CFO & Principal Accounting Officer More ExecutivesKey CompetitorsCogent BiosciencesNASDAQ:COGTPharming GroupNASDAQ:PHARBelite BioNASDAQ:BLTEInnovivaNASDAQ:INVAArdelyxNASDAQ:ARDXView All CompetitorsInsiders & InstitutionsBarclays PLCBought 12,474 shares on 9/21/2023Ownership: 0.190%California State Teachers Retirement SystemBought 5,085 shares on 8/21/2023Ownership: 0.082%Nuveen Asset Management LLCBought 15,180 shares on 8/16/2023Ownership: 0.276%Alliancebernstein L.P.Sold 3,100 shares on 8/15/2023Ownership: 0.119%Point72 Asset Management L.P.Bought 3,126 shares on 8/15/2023Ownership: 0.005%View All Insider TransactionsView All Institutional Transactions VERV Stock - Frequently Asked Questions Should I buy or sell Verve Therapeutics stock right now? 8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Verve Therapeutics in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" VERV shares. View VERV analyst ratings or view top-rated stocks. What is Verve Therapeutics' stock price forecast for 2023? 8 brokers have issued 1 year price objectives for Verve Therapeutics' shares. Their VERV share price forecasts range from $13.00 to $55.00. On average, they predict the company's share price to reach $30.83 in the next twelve months. This suggests a possible upside of 132.5% from the stock's current price. View analysts price targets for VERV or view top-rated stocks among Wall Street analysts. How have VERV shares performed in 2023? Verve Therapeutics' stock was trading at $19.35 at the beginning of the year. Since then, VERV shares have decreased by 31.5% and is now trading at $13.26. View the best growth stocks for 2023 here. When is Verve Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, November 6th 2023. View our VERV earnings forecast. How were Verve Therapeutics' earnings last quarter? Verve Therapeutics, Inc. (NASDAQ:VERV) released its quarterly earnings results on Thursday, August, 10th. The company reported ($0.87) earnings per share for the quarter, beating analysts' consensus estimates of ($0.90) by $0.03. The firm earned $2.10 million during the quarter, compared to analysts' expectations of $0.67 million. Verve Therapeutics had a negative trailing twelve-month return on equity of 37.08% and a negative net margin of 3,534.98%. The business's revenue for the quarter was up 2000.0% compared to the same quarter last year. What ETFs hold Verve Therapeutics' stock? ETFs with the largest weight of Verve Therapeutics (NASDAQ:VERV) stock in their portfolio include Kelly CRISPR & Gene Editing Technology ETF (XDNA), ARK Genomic Revolution ETF (ARKG), Direxion Moonshot Innovators ETF (MOON), WisdomTree BioRevolution Fund (WDNA), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Global X Genomics & Biotechnology ETF (GNOM) and ARK Innovation ETF (ARKK).iShares Micro-Cap ETF (IWC). When did Verve Therapeutics IPO? (VERV) raised $201 million in an initial public offering (IPO) on Thursday, June 17th 2021. The company issued 11,800,000 shares at $16.00-$18.00 per share. J.P. Morgan, Jefferies, Guggenheim Securities and William Blair acted as the underwriters for the IPO. What is Verve Therapeutics' stock symbol? Verve Therapeutics trades on the NASDAQ under the ticker symbol "VERV." How do I buy shares of Verve Therapeutics? Shares of VERV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Verve Therapeutics' stock price today? One share of VERV stock can currently be purchased for approximately $13.26. How much money does Verve Therapeutics make? Verve Therapeutics (NASDAQ:VERV) has a market capitalization of $844.93 million and generates $1.94 million in revenue each year. The company earns $-157,390,000.00 in net income (profit) each year or ($3.17) on an earnings per share basis. How many employees does Verve Therapeutics have? The company employs 204 workers across the globe. How can I contact Verve Therapeutics? The official website for the company is vervetx.com. The company can be reached via phone at 617-603-0070 or via email at ir@vervetx.com. This page (NASDAQ:VERV) was last updated on 10/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Verve Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.